



Slovakia

State Institute for Drug Control, Bratislava, PharmDr. Ján Mazag

Pricing

- **Price policies for pharmaceuticals**
Statutory pricing for reimbursable at pharmacy retail price and hospital-only pharmaceuticals at ex factory level. Free pricing for non-reimbursable OTC products
- **Wholesale mark-ups**
For all pharmaceuticals; Different linear mark-ups for different pharmaceuticals. (very expensive ph., vaccinations, non-reimbursable ph.)
- **Pharmacy mark-ups**
For all pharmaceuticals; Different linear mark-ups for different pharmaceuticals (very expensive ph., vaccinations, non-reimbursable ph.)
- **VAT**
in 2004-2006 19% standard rate also on pharmaceuticals, from 1.01.2007 VAT reduction for pharmaceuticals to 10%
- **Reforms**
From 1995: Reference price system for pharmaceuticals: External price reference system for ex-factory price (9 specific reference countries), Internal price reference system for retail price in ATC 4 or 5th level

Reimbursement

- **Positive list**
Issued quarterly, fixed ratio for reimbursement level and co-payment if co-payment generated from difference between retail price and reimbursement level. Approximately 5 000 pharmaceuticals listed in positive list from which 39 % are fully reimbursed or with patient co-payment maximally 0,3 € (as difference between retail price and reimbursement level)
- **Reference Price System**
Yes, Internal price reference system for retail price from 1995 as a result of clustering pharmaceuticals in ATC 4 or 5th level
- **Flat Co-payment**
In 2004 -2006: prescription fee of € 0,4 per prescription, change from 10 / 2006 to € 0,15 per prescription. Co-payments for ambulance visit (of € 0,4 per visit) and for bed-in-hospital (of 2,5 € per day) in 2004-2006 cancelled from 10 / 2006
- **Mechanisms for vulnerable groups**
Limit of maximum co-payment as maximum average of % from all % of co-payments in all reimbursable pharmaceuticals – defined in Act
- **Reforms**
From 2004: introduction of a new reimbursement process, composition of advisory body, price competition for interchangeable pharmaceuticals, frequency and evaluation of pharmaceuticals (direct cost analysis, budget impact, targeting population for new pharmaceuticals,...)